“…Whereas prospective outcome data on iron supplementation are lacking, given the very high safety profile of medicinal iron, irrespective of the route of administration, one could posit erring on the side of repletion and screening would be more prudent. Supporting this recommendation is a recently published study, referenced in the manuscript which is the subject of this editorial (Pavord et al , ), of 104 consecutive, non‐selected, non‐anaemic, first trimester gravidas who were screened for iron deficiency with tests for serum ferritin and percent transferrin saturation (Auerbach et al , ). Based on either serum ferritin or transferrin saturation, 42% were deficient, suggesting that the recommendations of the USPSTF should be revisited, moving towards a more aggressive paradigm of screening and treatment, to mitigate statistically significant negative outcomes in infants born with iron deficiency.…”